Right-to-try laws and individual patient “compassionate use” of experimental oncology medications
A call for improved provider-patient communication
Bibliographic Data
| ID | 12095280 |
|---|---|
| Authors | Michael Hoerger (0000-0002-4398-2820, Tulane University, corresponding author) |
| Year | 2015 |
| Volume | 40 |
| Issue | 2 |
| Pages | 113-120 |
| Publication date | 2015-08-27 |
| Open Access | No |
| Type | ARTICLE |
| Venue | Death Studies (JOURNAL) |
| Journal identifiers | ISSN: 0748-1187 • E-ISSN: 1091-7683 |
| Publisher | Taylor & Francis (PUBLISHER • GB) |
| DOI | 10.1080/07481187.2015.1077356 |
| PMID | 26313583 |
| OpenAlex | W2252060653 |
| Language | EN |
| References cited | 43 |
The U.S. Food and Drug Administration's Expanded Access program allows patients with life-threatening diagnoses, such as advanced cancer, to use experimental medications without participating in clinical research (colloquially, "Compassionate Use"). Sixteen U.S. states recently passed "right-to-try" legislation aimed at promoting Expanded Access. Acknowledging popular support, Expanded Access could undermine clinical trials that benefit public health. Moreover, existing norms in oncologic care, for example, often lead patients to pursue intense treatments near the end of life, at the expense of palliation, and improved communication about the risks and benefits of Expanded Access would more often discourage its use
Clinical trial · Compassionate Use · Expanded access · Family medicine · Food and drug administration · Intensive care medicine · Internet privacy · Legislation · Medical emergency · Biomedical Ethics and Regulation · Ethics in medical practice · Law · Medicine · Nursing · Palliative Care and End-of-Life Issues · Internal Medicine · Oncology
| Highly cited | No |
|---|